LRG-002

LRG-002 is a biological product developed for the prophylaxis of antibiotic-associated diarrhea (AAD), particularly in patients with acute respiratory diseases receiving standard antimicrobial therapy. The drug has been evaluated in a multicenter, double-blind, randomized, placebo-controlled Phase 3 clinical trial as an adjunct treatment to reduce the incidence of AAD. The original developer was Clariant AG, and subsequent development and clinical trials have been conducted by Sandoz. The product is formulated as oral hard capsules and was manufactured by Lek d.d., Slovenia (a Sandoz company). While the precise mechanism of action is not detailed in public sources, it is classified as a biological product intended to modulate gut flora or host response during antibiotic therapy.